Advanced Biomed Inc. Common Stock

Advanced Biomed Inc. (ADVB) reported a significant turnaround for the fiscal second quarter ended December 31, 2025, posting a net income of $6.9 million compared to historical losses. This profitability was driven almost entirely by a $7.3 million gain on the disposal of subsidiaries, contrasting with modest operating expenses of $397K. The company reported zero revenue for the period. Operating activities utilized $872K in cash, though financing activities provided $763K. The balance sheet reflects total assets of $10.9M against total liabilities of $1.4M, resulting in stockholders' equity of $9.5M. The disposal of subsidiaries marks a strategic pivot, significantly bolstering the company's financial position despite continued losses from discontinued operations of $144K. The company maintains a cash position of $2.6M from continuing operations.

Key Takeaways